Screener
Ligand Pharmaceuticals LGND Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Income tax receivable and payable | 522 | 2,758 |
| Deferred revenue | — | (578) |
| Other assets and liabilities | 980 | (6,247) |
| Net cash provided by (used in) operating activities | 72,709 | (9,646) |
| Cash flows from investing activities: | ||
| Acquisition of financial royalty assets | (2,640) | (1,821) |
| Proceeds from financial royalty assets | 9,500 | 5,179 |
| Purchases of derivatives | (2,672) | (7,620) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's operating cash flow?
- Ligand Pharmaceuticals (LGND) reported operating cash flow of $24.02M in Q2 2026.
- How has Ligand Pharmaceuticals's operating cash flow changed year-over-year?
- Ligand Pharmaceuticals's operating cash flow increased by 52.0% year-over-year, from $15.8M to $24.02M.
- What is the long-term trend for Ligand Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's operating cash flow has grown at a -11.0% compound annual growth rate (CAGR), from $78.8M to $49.36M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Ligand Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude